{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T13:43:29Z","timestamp":1693316609321},"reference-count":120,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CD19\u2010directed chimeric antigen receptor T\u2010cell therapy (CAR\u2010T) represents a significant advancement for patients with relapsed\/refractory large B\u2010cell lymphoma (LBCL). Long\u2010term follow\u2010up confirms durable remissions in nearly half of the patients, a population that was previously estimated to have a median survival of around 6 months with standard salvage therapy. This initial success of CAR\u2010T has led to significant expansion across other lymphoma histologies resulting in the recent regulatory approval of CAR\u2010T in mantle cell lymphoma and follicular lymphoma. Additionally, multiple novel platforms of CAR\u2010T therapy are under development to improve efficacy and limit toxicity such dual antigen targeting, allogeneic and natural killer CARs. In this review, we focus on the new indications of CAR\u2010T in lymphomas beyond LBCL as well as emerging platforms of CAR\u2010T therapy.<\/jats:p>","DOI":"10.1002\/jha2.323","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T08:51:19Z","timestamp":1637657479000},"page":"11-23","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["New indications and platforms for CAR\u2010T therapy in lymphomas beyond DLBCL"],"prefix":"10.1002","volume":"3","author":[{"given":"Madiha","family":"Iqbal","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology Mayo Clinic  Jacksonville Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipin N","family":"Savani","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Vanderbilt University  Nashville Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"Blood &amp; Marrow Transplantation and Cellular Therapy Program Division of Hematology and Oncology Medical College of Wisconsin  Milwaukee Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01467"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25487"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25696"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22367"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.72"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6278"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13796"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu097"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14241"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0539"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205229"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2380"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136158"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0977"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.03.001"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00400"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00169-2"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4648"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00915"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.771"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.028"},{"key":"e_1_2_12_37_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-136834","article-title":"Primary analysis of Zuma\u20105: a phase 2 study of axicabtagene ciloleucel (Axi\u2010Cel) in patients with relapsed\/refractory (R\/R) indolent non\u2010Hodgkin lymphoma (iNHL)","volume":"136","author":"Jacobson C","year":"2020","journal-title":"Blood"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135871"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7548"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138983"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-136242"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00340-z"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15149"},{"key":"e_1_2_12_44_1","unstructured":"Paola GhioneAP SBobillo KDeighton CJacobson MNahas&AHatswellet al. A Comparison of clinical outcomes from zuma\u20105 (axicabtagene ciloleucel) and the international scholar\u20105 external control cohort in relapsed\/refractory follicular lymphoma (R\/R FL).https:\/\/library.ehaweb.org\/eha\/2021\/eha2021\u2010virtual\u2010congress\/330174\/john.gribben.a.comparison.of.clinical.outcomes.from.zuma\u20105.28axicabtagene.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Da+comparison%2Bclinical+outcomes%2Bzuma%E2%80%90"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007445"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1061-7"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.18.9699"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90180-K"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01342"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1365"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI94306"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/08820130500496878"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03279"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1081-3"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0"},{"issue":"1","key":"e_1_2_12_57_1","first-page":"600","article-title":"Phase 1 alexander study of AUTO3, the first CD19\/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed\/refractory (r\/r) DLBCL","volume":"136","author":"Ramakrishnan A","year":"2020","journal-title":"Blood"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.08.012"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0201-9"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629527"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129559"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e14510"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4444"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad5222"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2155-7"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-683847"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0956-8"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-755496"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2017.09.005"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00307"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1300"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0065-5"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3321"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.59"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.12.009"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.142"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-478255"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3860"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-486324"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-289991"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.03.569"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.353.353"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618427"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0062-8"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00462-8"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2018.09.007"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.03.013"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13586"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00456"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0089-y"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010813"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(03)90004-2"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2974"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607"},{"key":"e_1_2_12_100_1","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1200\/JCO.2021.39.15_suppl.7541","article-title":"Preliminary results of a phase I trial of FT516, an off\u2010the\u2010shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high\u2010affinity, non\u2010cleavable CD16 (hnCD16), in patients (pts) with relapsed\/refractory (R\/R) B\u2010cell lymphoma (BCL)","volume":"39","author":"Strati P","year":"2021","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2782"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8002"},{"key":"e_1_2_12_103_1","unstructured":"TherapeuticsA.Allogene therapeutics presents positive Phase 1 data on ALLO\u2010501 and ALLO\u2010501A in relapsed\/refractory non\u2010Hodgkin lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology Allogene Therapeutics.2021."},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.02.005"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.03.001"},{"key":"e_1_2_12_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128203"},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7516"},{"key":"e_1_2_12_108_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1231143"},{"key":"e_1_2_12_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15218"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405"},{"key":"e_1_2_12_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2018.04.003"},{"key":"e_1_2_12_113_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7570"},{"key":"e_1_2_12_114_1","doi-asserted-by":"crossref","unstructured":"QuachDH Ganesh HR Thakkar S Becerra\u2010Dominguez L Mehta B Perconti S et\u00a0al.A bank of CD30.CAR\u2010Modified Epstein\u2010Barr virus\u2010specific T cells that lacks host reactivity and resists graft rejection for patients with CD30\u2010positive lymphoma. 2021 American Society of Gene and Cell Therapy Annual Meeting; May 11\u201314 2021; Virtual Abstract 195.2021.","DOI":"10.1182\/blood-2020-141491"},{"key":"e_1_2_12_115_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081926"},{"key":"e_1_2_12_116_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3451"},{"issue":"1347","key":"e_1_2_12_117_1","article-title":"Gamma\u2010delta CAR\u2010T cells show CAR\u2010directed and independent activity against leukemia","volume":"11","author":"Rozenbaum M","year":"2020","journal-title":"Front Immunol"},{"key":"e_1_2_12_118_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1527"},{"key":"e_1_2_12_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947"},{"key":"e_1_2_12_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001694"},{"key":"e_1_2_12_121_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004106"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.323","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.323","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:12:06Z","timestamp":1693203126000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":120,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1002\/jha2.323"],"URL":"https:\/\/doi.org\/10.1002\/jha2.323","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]},"assertion":[{"value":"2021-09-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}